Discover and read the best of Twitter Threads about #Hester
Most recents (2)
The outlook for #Hester Biosciences’ does not seem very strong for the next year. They are facing major issues in multiple segments. Some takeaways from their Q2 FY23 concalls below⚠️⚠️
Their poultry business, which is their largest vertical, is not doing well as cost of raw materials has increased and demand for the end product has been decreasing. Poultry farmers are trying to reduce input costs which means lower demand for Hester’s products. 
The company’s product mix is shifting from mainly vaccines toward animal health products which are generally lower in margin than vaccines. This issue is also made worse by the increase in raw material prices for their health products which is further reducing margins.
# HESTER BIOSCIENCES LTD
CMP is 1240 , MCAP 1050 Cr , Promoters holding around 54% , Good growth till Fy 19 , FY 19-20 was weak ,Dividend paying company ,BV 236 , Small equity
CMP is 1240 , MCAP 1050 Cr , Promoters holding around 54% , Good growth till Fy 19 , FY 19-20 was weak ,Dividend paying company ,BV 236 , Small equity
Started business in 1987 as a trading company, now second largest poultry vaccine manufacturer in India ( largest is venkys ) with two manufacturing unit in Ahmedabad and Nepal . Diagnostic lab - Anand , Hyderabad
Company operates through 4 verticals
1-Poultry vaccines
2-Animal vaccines
3-Poultry health products
4- Animal health products
Company is having around 50 vaccines and 35 health products
1-Poultry vaccines
2-Animal vaccines
3-Poultry health products
4- Animal health products
Company is having around 50 vaccines and 35 health products
